Belzutifan Practical Guidance in Advanced Clear-Cell RCC

Authored by Natalia Gandur, published on 2026-07-08 09:53:09.0

This belzutifan-focused pathway is broadly aligned with current evidence and labeling for advanced/metastatic ccRCC after prior PD-(L)1 inhibitor and VEGF-targeted therapy, centering on LITESPARK-005 and the WELIREG prescribing information. The algorithm appropriately emphasizes baseline and on-treatment monitoring for mechanism-related anemia and hypoxia and includes pragmatic dose interruption/reduction concepts. Its scope is appropriately narrow (monotherapy, later-line) and correctly defers broader sequencing to other pathways.

Confirm advanced clear-cell RCC treatment context

This pathway applies to adults with advanced or metastatic renal cell carcinoma with a clear-cell component who are being considered for belzutifan monotherapy. Confirm: - Clear-cell RCC or RCC with a clear-cell component - Advanced, unresectable, or metastatic disease - Prior systemic therapy history - Prior PD-1 or PD-L1 inhibitor exposure - Prior VEGF-TKI exposure - Current disease burden and sites of metastases - Disease tempo and symptoms - ECOG performance status - Prior immune-related adverse events - Prior VEGF-TKI toxicity - Comorbidities, pulmonary status, anemia risk, patient goals, access, and logistics This is an advanced/metastatic ccRCC belzutifan monotherapy pathway. This is not: - an adjuvant pembrolizumab + belzutifan pathway; - a VHL-associated RCC pathway; - a PPGL pathway; - a non-clear-cell RCC pathway; - a broad RCC sequencing pathway.
- Prior PD-(L)1 inhibitor and VEGF-TKI exposure?
  
  Belzutifan monotherapy is most directly supported in advanced clear-cell RCC after prior PD-1 or PD-L1 inhibitor and VEGF-TKI exposure. Confirm whether the patient has received: - PD-1 or PD-L1 checkpoint inhibitor - VEGF-TKI - Both therapies either sequentially or in combination - Number of prior systemic therapy lines - Prior mTOR inhibitor, HIF-2α inhibitor, or investigational therapy if any - Reason for prior treatment discontinuation: progression, toxicity, patient preference, access, or other reason If the patient has not received prior PD-(L)1 inhibitor and VEGF-TKI exposure, use an appropriate first-line or earlier-line RCC pathway, clinical trial, or expert-guided alternative strategy.
  - Use appropriate RCC pathway / clinical trial
    
    If the patient does not fit the advanced ccRCC post–PD-(L)1 and VEGF-TKI treatment context, use the appropriate RCC pathway. Consider: - First-line advanced ccRCC treatment-selection pathway - Subsequent-line RCC sequencing pathway - Adjuvant RCC pathway if post-nephrectomy without metastatic progression - VHL-associated RCC pathway if applicable - Non-clear-cell RCC pathway if non-clear-cell histology predominates - PPGL pathway if relevant - Clinical trial when available This is a terminal hand-off node, not a loop.
  - Confirm this is the advanced ccRCC belzutifan monotherapy scenario
    
    Before proceeding, confirm that the patient belongs in this advanced ccRCC belzutifan monotherapy pathway. This pathway is for: - Advanced or metastatic clear-cell RCC or RCC with a clear-cell component - Prior PD-(L)1 inhibitor exposure - Prior VEGF-TKI exposure - Consideration of belzutifan monotherapy Separate pathways should be used for: - Adjuvant pembrolizumab + belzutifan after nephrectomy - VHL-associated RCC or other VHL-associated tumors - Locally advanced, unresectable, or metastatic PPGL - Non-clear-cell RCC without a clear-cell component - First-line advanced RCC treatment selection - Broad RCC sequencing decisions outside the belzutifan-specific use case This algorithm is designed as a focused practical guidance pathway for belzutifan monotherapy in advanced ccRCC after prior PD-(L)1 inhibitor and VEGF-TKI.
    - Assess suitability for belzutifan
      
      Assess whether belzutifan is clinically appropriate, feasible, and aligned with patient goals. Consider: - Baseline hemoglobin and anemia symptoms - Transfusion history or need - Baseline oxygen saturation at rest - Oxygen saturation with exertion if clinically relevant - Pulmonary comorbidities, COPD, interstitial lung disease, oxygen requirement, or dyspnea - Lung metastases or pleural disease - Cardiovascular status - Renal and hepatic function - ECOG performance status and frailty - Fatigue burden - Prior therapy tolerance - Drug interactions - Reproductive potential and contraception counseling - Oral therapy adherence - Access, payer requirements, and local approval Belzutifan may be particularly useful when an oral, non-VEGF, non-IO mechanism is appropriate, but baseline anemia and hypoxia risk must be assessed carefully. Patients with significant baseline anemia, borderline oxygen saturation, oxygen requirement, or substantial pulmonary comorbidity require individualized risk-benefit discussion and closer monitoring.
      - Baseline hemoglobin and oxygen saturation assessment
        
        Before starting belzutifan, obtain and document baseline safety parameters. Required baseline safety assessment: - CBC with differential - Hemoglobin - Platelet count - Renal function - Liver tests - Oxygen saturation at rest - Pulmonary symptoms - Dyspnea assessment - Need for supplemental oxygen - Medication review - Pregnancy status when relevant Baseline iron panel: - Ferritin- Serum iron - Transferrin saturation - Total iron-binding capacity (TIBC) Assess for iron deficiency even when hemoglobin is near-normal or within the normal range, particularly because belzutifan-related anemia may develop during treatment and baseline iron deficiency can confound attribution and management.Baseline iron panel should be obtained to rule out iron deficiency anemia, even in patients whose hemoglobin is close to normal values or within the normal range. Consider additional assessment when clinically indicated: - Oxygen saturation with exertion - Chest imaging review - Pulmonary evaluation in patients with borderline oxygenation or significant lung disease - Evaluation of reversible anemia contributors such as bleeding, iron deficiency, B12/folate deficiency, renal dysfunction, inflammation, or marrow involvement A patient with significant baseline anemia, symptomatic dyspnea, oxygen requirement, or borderline oxygen saturation may still be considered in selected cases, but this requires individualized risk-benefit discussion and closer monitoring. This node functions as the main safety gate before treatment initiation.
        
        Is belzutifan appropriate, safe, and available?
        
        Proceed with belzutifan if: - Advanced/metastatic ccRCC treatment context is confirmed - Prior PD-(L)1 inhibitor and VEGF-TKI exposure is documented - No better pathway applies - Baseline hemoglobin is acceptable or manageable - Baseline oxygen saturation is acceptable or manageable - Pulmonary risk is acceptable or manageable - Patient can comply with monitoring - Access and regulatory/payer requirements support treatment - Patient understands anemia, hypoxia, fatigue, dyspnea, and monitoring requirements If belzutifan is not appropriate, safe, or available, use an alternative standard RCC next-line pathway, clinical trial, best supportive care when appropriate, or expert multidisciplinary review.
        
        Alternative standard next-line RCC pathway / clinical trial
        
        Use an alternative RCC next-line strategy when belzutifan is not clinically appropriate, not available, not preferred, or not supported by local access/regulatory criteria. Consider: - VEGFR-TKI sequencing - Tivozanib, cabozantinib, lenvatinib/everolimus, axitinib, or other locally available options according to prior exposure and guideline context - Clinical trial - Best supportive care when appropriate - Local therapy for oligoprogression when clinically relevant - Symptom burden, disease tempo, prior toxicities, comorbidities, access, and patient goals This is a terminal hand-off node, not a loop.
        
        Start belzutifan
        
        Start belzutifan according to prescribing information and local guidance. Standard adult dose:- Belzutifan 120 mg orally once daily- With or without food- Continue until disease progression or unacceptable toxicity Administration counseling: - Take at the same time each day - Swallow tablets whole - Do not chew, crush, or split tablets - If a dose is missed, it can be taken as soon as possible on the same day; resume the regular schedule the next day - Do not take extra doses to make up for a missed dose - If vomiting occurs after taking a dose, do not retake the dose; take the next dose the following day Counsel patients regarding:- Anemia and fatigue- Hypoxia and dyspnea- Need to report shortness of breath, dizziness, worsening fatigue, chest symptoms, or oxygen desaturation- Reproductive risks and need for effective non-hormonal contraception when relevant- Potential drug interactions
        
        Monitoring during therapy
        
        Monitor closely during belzutifan therapy, especially early in treatment. Suggested monitoring: - CBC with differential and hemoglobin at baseline and periodically during treatment - More frequent CBC monitoring during the first 1–2 months or if hemoglobin declines - Oxygen saturation at baseline and periodically during treatment - Oxygen saturation sooner if dyspnea, fatigue, dizziness, chest symptoms, pulmonary disease, lung metastases, or borderline baseline saturation - Renal function - Liver tests - Electrolytes as clinically indicated - Fatigue, dizziness, headache, nausea, appetite, dyspnea, and functional status - Need for transfusion, oxygen, dose hold, dose reduction, or hospitalization - Adherence and medication interactions - Imaging response according to RCC follow-up practice and clinical context Belzutifan monitoring should focus especially on anemia and hypoxia, which are mechanism-related and clinically important toxicities. Other adverse effects and laboratory abnormalities may include: - Fatigue - Musculoskeletal pain - Increased creatinine - Increased ALT/AST - Decreased lymphocytes - Electrolyte abnormalities - Nausea - Dizziness - Dyspnea - Rash - Hypertension - Visual symptoms or visual impairment - Hemorrhage in selected cases Implementation considerations: - Review concomitant medications - Monitor for anemia and hypoxia more closely when using UGT2B17 or CYP2C19 inhibitors - Avoid coadministration with sensitive CYP3A4 substrates when decreased concentration may reduce substrate efficacy - Counsel regarding embryo-fetal toxicity - Use effective non-hormonal contraception when relevant, because belzutifan may reduce the effectiveness of some hormonal contraceptives - Consider fertility counseling when relevant
        
        Anemia management
        
        Belzutifan can cause clinically significant anemia. If hemoglobin declines:Before attributing anemia entirely to belzutifan, evaluate for reversible or coexisting contributors. Iron deficiency assessment: - Review baseline iron panel when available. - Repeat iron studies if hemoglobin declines, anemia symptoms develop, or fatigue/dyspnea is disproportionate. - Include ferritin, serum iron, transferrin saturation, and TIBC. - Correct iron deficiency when clinically appropriate according to local practice. Iron deficiency should be considered even if baseline hemoglobin was near-normal or within the normal range. - Assess symptoms and rate of decline - Evaluate for bleeding, iron deficiency, B12/folate deficiency, renal dysfunction, inflammation, marrow involvement, and disease progression when clinically relevant - Consider transfusion as clinically indicated - Consider treatment interruption, dose reduction, or discontinuation according to severity and prescribing information - Reassess functional status, dyspnea, fatigue, and oxygenation For advanced ccRCC and other non-adjuvant indications: - If hemoglobin is <8 g/dL or transfusion is indicated, withhold belzutifan until hemoglobin is ≥8 g/dL. - Resume at the same or reduced dose, or discontinue depending on severity. - For life-threatening anemia or urgent intervention, withhold until hemoglobin is ≥8 g/dL, then resume at reduced dose once resolved or permanently discontinue. Dose reduction sequence: - First dose reduction: 80 mg orally once daily - Second dose reduction: 40 mg orally once daily - Third dose reduction: permanently discontinue ESA use should be individualized and interpreted cautiously according to label guidance, disease context, thrombosis risk, local practice, and expert review.
        
        Hypoxia management
        
        Belzutifan can cause clinically significant hypoxia. Monitor oxygen saturation before starting and periodically during therapy. If oxygen saturation decreases with exercise, for example pulse oximeter <88% or PaO2 ≤55 mm Hg: - Consider withholding belzutifan until resolved - Resume at the same or reduced dose depending on severity If oxygen saturation decreases at rest, for example pulse oximeter <88% or PaO2 ≤55 mm Hg, or urgent intervention is indicated: - Withhold belzutifan until resolved - Resume at a reduced dose or discontinue depending on severity For life-threatening hypoxia or recurrent symptomatic hypoxia: - Permanently discontinue belzutifan Evaluate for alternative or contributing causes: - Pulmonary embolism - Pneumonia - Pleural effusion - Progressive lung metastases - COPD or interstitial lung disease - Cardiac disease - Anemia - Drug-related pneumonitis from prior or concurrent therapies when relevant Patients should be counseled to report dyspnea, new oxygen requirement, chest symptoms, dizziness, or worsening fatigue promptly.
        
        Response assessment
        
        Assess response using standard RCC clinical and radiographic follow-up. Consider: - Symptoms and performance status - Disease-related pain - Weight, appetite, and functional trajectory - Imaging by RECIST-oriented practice when appropriate - Sites at risk: lung, bone, lymph nodes, liver, brain if clinically indicated - Treatment tolerance and cumulative toxicity - Patient goals and quality of life Belzutifan may have a different toxicity profile than VEGF-TKIs or immune checkpoint inhibitors. Treatment continuation should be based on disease control, tolerability, patient goals, and absence of unacceptable toxicity. If there is mixed response or oligoprogression, consider multidisciplinary review and local therapy where appropriate, but avoid looping within this algorithm.
        
        Progression or unacceptable toxicity: next-line hand-off
        
        At radiographic progression, clinical progression, or unacceptable toxicity, reassess the full RCC context. Confirm: - Prior PD-(L)1 exposure - Prior VEGF-TKI exposure - Prior mTOR inhibitor exposure - Prior belzutifan exposure and reason for discontinuation - Disease tempo - Symptom burden - Sites of progression - Performance status - Organ function - Eligibility for clinical trial - Suitability for VEGFR-TKI, mTOR-based therapy, other systemic options, local therapy, or best supportive care Terminal hand-off: Open post-belzutifan RCC sequencing pathway, clinical trial pathway, local therapy review, or best supportive care pathway when appropriate. Key caveats: - This algorithm is focused on belzutifan monotherapy for advanced clear-cell RCC after prior PD-(L)1 inhibitor and VEGF-TKI exposure. - Do not mix this pathway with adjuvant pembrolizumab + belzutifan, VHL-associated RCC, PPGL, or non-clear-cell RCC; these require separate algorithms. - The central implementation issue is not only whether belzutifan is indicated, but whether the patient can be safely monitored and managed for anemia and hypoxia. - Baseline hemoglobin and oxygen saturation should be documented before starting therapy. - Patients with baseline anemia, pulmonary comorbidity, lung metastases, oxygen requirement, or borderline oxygen saturation require individualized risk-benefit discussion and closer monitoring. - Dose interruption and reduction are key safety tools. Dose reduction sequence is 120 mg → 80 mg → 40 mg → discontinue. - Expert faculty review is recommended, particularly for borderline oxygenation, severe baseline anemia, unusual sequencing, adjuvant/post-adjuvant relapse, or non-clear-cell histology. This is a terminal node. Do not loop back to earlier belzutifan selection steps.

tos privacy Choueiri TK, Powles T, Peltola K, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024;391:710-721.Choueiri TK, Bauer TM, Papadopoulos KP, et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021;27:802-805. PMID: 33888901.WELIREG (belzutifan) Prescribing Information. Merck. Revised June 2026.LITESPARK-005 / NCT04195750: Belzutifan versus Everolimus in Advanced Clear-Cell RCC.FDA approves belzutifan for advanced renal cell carcinoma.Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021;385:2036-2046. PMID: 34818478.